Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
August 26, 2021 16:05 ET
|
Bolt Biotherapeutics, Inc.
Innovent will provide proprietary antibodies for selected tumor targets and Bolt will provide its proprietary Boltbody™ technology to create new immune-stimulating antibody conjugates (ISACs)Innovent...
Bolt Biotherapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights
August 12, 2021 16:05 ET
|
Bolt Biotherapeutics, Inc.
– BDC-1001 Phase 1/2 trial in HER2-expressing solid tumors on track for data update in 2H 2021– – Announced R&D collaboration with Genmab to develop multiple bispecific ISACs for treatment of...
Bolt Biotherapeutics Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021
June 04, 2021 09:00 ET
|
Bolt Biotherapeutics, Inc.
Poster showcases positive preliminary data from first 20 patients treated with the HER2-targeting Boltbody™ ISAC BDC-1001 as of January 29th cutoff dateMonotherapy dose expansion and anti-PD-1...
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
June 02, 2021 08:00 ET
|
Bolt Biotherapeutics, Inc.
Media Release Collaboration to discover and evaluate novel product concepts based on the combination of Genmab’s antibodies and bispecific antibody technologies with Bolt’s proprietary...
Bolt Biotherapeutics Reports First Quarter 2021 Financial Results and Provides Business Highlights
May 13, 2021 16:05 ET
|
Bolt Biotherapeutics, Inc.
– Strong cash position of $302.9 million as of March 31, 2021 expected to deliver key value-creating milestones and fund operations into 2023 – – Upsized IPO in February 2021 raised $264.5 million in...
Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody™ Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001
April 10, 2021 08:30 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that...
Bolt Biotherapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
April 08, 2021 07:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the...
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
March 31, 2021 16:05 ET
|
Bolt Biotherapeutics, Inc.
– Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising – – Advanced first-in-class Boltbody™...
Bolt Biotherapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
February 09, 2021 16:05 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public...
Bolt Biotherapeutics Prices Upsized Initial Public Offering
February 04, 2021 22:34 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the pricing of its upsized initial public...